一种用于抗板层素332黏膜类天疱疮血清学诊断的敏感且特异的检测方法
本研究开发了一种基于重组板层素332的间接免疫荧光检测法,用于检测抗板层素332黏膜类天疱疮(MMP)患者血清抗体。在93例抗板层素332 MMP患者中,异源三聚体灵敏度为77%,对α3、β3、γ2单链灵敏度分别为43%、41%、13%,各底物特异度均为100%。抗板层素332反应性与疾病活动度平行,25%患者伴发恶性肿瘤。
要点
- 新型间接免疫荧光法检测抗板层素332抗体,异源三聚体灵敏度77%,特异度100%。
- 抗板层素332反应性与疾病活动度平行,25%抗板层素332 MMP患者伴发恶性肿瘤。
- 该检测有助于抗板层素332 MMP的血清学诊断及识别恶性肿瘤风险患者。
核心结论
- 新型间接免疫荧光检测法有助于抗板层素332黏膜类天疱疮的血清学诊断,并可能帮助识别有恶性肿瘤风险的患者。
研究设计与样本
- 开发基于重组板层素332的间接免疫荧光检测法,检测93例抗板层素332 MMP患者血清,以及153例抗板层素332阴性MMP、20例大疱性类天疱疮、20例寻常型天疱疮、22例非炎症性皮肤病和100例健康献血者血清。
主要发现
- 异源三聚体灵敏度77%,α3、β3、γ2单链灵敏度分别为43%、41%、13%,各底物特异度均为100%。
- 应用抗IgG4富集的抗总IgG结合物时,异源三聚体的灵敏度提高。
- 抗板层素332反应性与疾病活动度平行。
- 25%的抗板层素332 MMP患者伴发恶性肿瘤。
关键数值与推荐
- 异源三聚体灵敏度77%,特异度100%;α3链灵敏度43%,β3链灵敏度41%,γ2链灵敏度13%,各底物特异度均为100%。
临床怎么用
- 该检测有助于抗板层素332黏膜类天疱疮的血清学诊断,并可能帮助识别有恶性肿瘤风险的患者。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Antilaminin 332 mucous membrane pemphigoid (MMP) is an autoimmune subepidermal blistering disease with predominant mucosal involvement and autoantibodies against laminin 332. Malignancies have been associated with this disease; however, no standardized detection system for antilaminin 332 serum antibodies is widely available. OBJECTIVES: Development of a sensitive and specific assay for the detection of antilaminin 332 antibodies. METHODS: An indirect immunofluorescence (IF) assay using recombinant laminin 332 was developed and probed with a large number of antilaminin 332 MMP patient sera (n = 93), as well as sera from patients with antilaminin 332-negative MMP (n = 153), bullous pemphigoid (n = 20), pemphigus vulgaris (n = 20) and noninflammatory dermatoses (n = 22), and healthy blood donors (n = 100). RESULTS: In the novel IF assay, sensitivities with the laminin 332 heterotrimer and the individual α3, β3 and γ2 chains were 77%, 43%, 41% and 13%, respectively, with specificities of 100% for each substrate. The sensitivity for the heterotrimer increased when an anti-IgG4 enriched antitotal IgG conjugate was applied. Antilaminin 332 reactivity paralleled disease activity and was associated with malignancies in 25% of patients with antilaminin 332 MMP. CONCLUSIONS: The novel IF-based assay will facilitate the serological diagnosis of antilaminin 332 MMP and may help to identify patients at risk of a malignancy.
引用
- Goletz S, Probst C, Komorowski L, et al. A sensitive and specific assay for the serological diagnosis of antilaminin 332 mucous membrane pemphigoid. Br J Dermatol. 2018. PMID: 30216412. doi:10.1111/bjd.17202
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。